Hormonal
GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk.
If you have Type 2 Diabetes and are at high risk for heart problems, ask your doctor about GLP-1 RAs like liraglutide or semaglutide. These drugs not only help control blood sugar but have been proven in major studies to significantly lower your risk of heart attack, stroke, and cardiovascular death. The benefits extend beyond glucose control to direct heart protection.
Recent cardiovascular outcome trials involving GLP-1 receptor agonists, especially liraglutide and semaglutide, have shown a significant reduction in major adverse cardiovascular events (MACE) among patients with type 2 diabetes at high risk for cardiovascular disease (14, 36).
Why this rating
Supported by multiple large-scale randomized controlled trials (LEADER, SUSTAIN-6, etc.) with statistically significant hazard ratios.
Source
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Bisma Fatima Hammad et al. · Frontiers in Clinical Diabetes and Healthcare · 2025
DOI 10.3389/fcdhc.2025.1590530
More from this paper
- GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.Strong
- GLP-1 receptor agonists provide neuroprotective benefits, including potential improvement in cognitive function and reduction in neurodegenerative disease progression (Alzheimer's and Parkinson's).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →